MX2019001672A - Composiciones de poxvirus quiméricos y usos de las mismas. - Google Patents
Composiciones de poxvirus quiméricos y usos de las mismas.Info
- Publication number
- MX2019001672A MX2019001672A MX2019001672A MX2019001672A MX2019001672A MX 2019001672 A MX2019001672 A MX 2019001672A MX 2019001672 A MX2019001672 A MX 2019001672A MX 2019001672 A MX2019001672 A MX 2019001672A MX 2019001672 A MX2019001672 A MX 2019001672A
- Authority
- MX
- Mexico
- Prior art keywords
- chemeric
- poxvirus
- things
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662372408P | 2016-08-09 | 2016-08-09 | |
| US201762519010P | 2017-06-13 | 2017-06-13 | |
| PCT/US2017/046163 WO2018031694A1 (en) | 2016-08-09 | 2017-08-09 | Chimeric poxvirus compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001672A true MX2019001672A (es) | 2019-06-06 |
Family
ID=61163330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001672A MX2019001672A (es) | 2016-08-09 | 2017-08-09 | Composiciones de poxvirus quiméricos y usos de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12084687B2 (https=) |
| EP (1) | EP3497209A4 (https=) |
| JP (4) | JP7023929B2 (https=) |
| KR (3) | KR20230113832A (https=) |
| CN (3) | CN118853594A (https=) |
| AU (2) | AU2017311380A1 (https=) |
| CA (1) | CA3033512A1 (https=) |
| MX (1) | MX2019001672A (https=) |
| RU (2) | RU2757002C2 (https=) |
| WO (1) | WO2018031694A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| CN115300622A (zh) | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| KR20180133395A (ko) | 2016-02-25 | 2018-12-14 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스 |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| KR20230113832A (ko) * | 2016-08-09 | 2023-08-01 | 시티 오브 호프 | 키메라 폭스바이러스 조성물 및 이의 용도 |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| WO2019033030A1 (en) * | 2017-08-11 | 2019-02-14 | City Of Hope | ONCOLYTIC VIRUS EXPRESSING A CAR-T CELL TARGET AND USES THEREOF |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| CA3093093A1 (en) * | 2018-03-07 | 2019-09-12 | Transgene | Parapoxvirus vectors |
| WO2019213173A1 (en) * | 2018-04-30 | 2019-11-07 | City Of Hope | Neural stem cell compositions including chimeric poxviruses for cancer treatment |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| CN113583977B (zh) * | 2020-04-30 | 2025-06-06 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| WO2023213763A1 (en) * | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| US20260049291A1 (en) | 2022-08-18 | 2026-02-19 | Transgene | Chimeric poxviruses |
| WO2024245722A2 (en) * | 2023-05-26 | 2024-12-05 | Probiogen Ag | Rapid selection system for the generation of recombinant enveloped viruses |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
| CN120718864B (zh) * | 2025-08-28 | 2025-11-28 | 山东农业大学 | 一种高度不成熟鸭坦布苏病毒及其培养方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT406376B (de) | 1998-01-16 | 2000-04-25 | Immuno Ag | Chimäres poxvirus enthaltend eine retrovirale vektorkomponente |
| EP1268763A2 (en) | 2000-03-28 | 2003-01-02 | University Of Rochester | Methods of producing a library and methods of selecting polynucleotides |
| CA2501168A1 (en) * | 2002-11-25 | 2004-06-10 | Bavarian Nordic A/S | Recombinant poxvirus comprising at least two cowpox ati promoters |
| ATE420160T1 (de) * | 2003-06-18 | 2009-01-15 | Genelux Corp | Modifizierte rekombinante vacciniaviren, verwendungen davon |
| EP2097517B1 (en) | 2006-10-16 | 2014-06-04 | Genelux Corporation | Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody |
| HRP20150360T1 (hr) * | 2007-11-19 | 2015-05-08 | Transgene Sa | Poksvirusni onkolitiäśki vektori |
| US20130071430A1 (en) * | 2010-04-09 | 2013-03-21 | The University Of Tokyo | Microrna-controlled recombinant vaccinia virus and use thereof |
| ES2733211T3 (es) | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| JP2015520754A (ja) | 2012-05-18 | 2015-07-23 | オタゴ イノベーション リミテッド | 創傷治癒のための組合せ治療および組成物 |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| KR20230113832A (ko) * | 2016-08-09 | 2023-08-01 | 시티 오브 호프 | 키메라 폭스바이러스 조성물 및 이의 용도 |
-
2017
- 2017-08-09 KR KR1020237024342A patent/KR20230113832A/ko not_active Ceased
- 2017-08-09 CA CA3033512A patent/CA3033512A1/en active Pending
- 2017-08-09 CN CN202410528631.4A patent/CN118853594A/zh active Pending
- 2017-08-09 EP EP17840232.7A patent/EP3497209A4/en active Pending
- 2017-08-09 JP JP2019507161A patent/JP7023929B2/ja active Active
- 2017-08-09 US US16/324,541 patent/US12084687B2/en active Active
- 2017-08-09 CN CN201780062335.8A patent/CN110199018B/zh active Active
- 2017-08-09 KR KR1020257014373A patent/KR20250067190A/ko active Pending
- 2017-08-09 AU AU2017311380A patent/AU2017311380A1/en not_active Abandoned
- 2017-08-09 CN CN202410528486.XA patent/CN118834840A/zh active Pending
- 2017-08-09 WO PCT/US2017/046163 patent/WO2018031694A1/en not_active Ceased
- 2017-08-09 KR KR1020197006987A patent/KR102557818B1/ko active Active
- 2017-08-09 RU RU2019106319A patent/RU2757002C2/ru active
- 2017-08-09 RU RU2021128158A patent/RU2021128158A/ru unknown
- 2017-08-09 MX MX2019001672A patent/MX2019001672A/es unknown
-
2022
- 2022-02-08 JP JP2022017693A patent/JP7395628B2/ja active Active
-
2023
- 2023-11-20 AU AU2023270200A patent/AU2023270200B2/en active Active
- 2023-11-28 JP JP2023200433A patent/JP7631485B2/ja active Active
-
2024
- 2024-07-17 US US18/776,109 patent/US20250084384A1/en active Pending
-
2025
- 2025-02-04 JP JP2025016649A patent/JP2025072482A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7631485B2 (ja) | 2025-02-18 |
| JP7395628B2 (ja) | 2023-12-11 |
| CN110199018A (zh) | 2019-09-03 |
| JP2024026191A (ja) | 2024-02-28 |
| CA3033512A1 (en) | 2018-02-15 |
| RU2021128158A (ru) | 2022-04-07 |
| CN118853594A (zh) | 2024-10-29 |
| AU2017311380A1 (en) | 2019-03-28 |
| RU2757002C2 (ru) | 2021-10-08 |
| KR102557818B1 (ko) | 2023-07-20 |
| US20190218522A1 (en) | 2019-07-18 |
| WO2018031694A1 (en) | 2018-02-15 |
| BR112019002646A2 (pt) | 2019-10-08 |
| AU2023270200A1 (en) | 2024-01-25 |
| EP3497209A1 (en) | 2019-06-19 |
| EP3497209A4 (en) | 2020-07-29 |
| RU2019106319A3 (https=) | 2021-03-17 |
| CN118834840A (zh) | 2024-10-25 |
| US20250084384A1 (en) | 2025-03-13 |
| JP2022065034A (ja) | 2022-04-26 |
| JP2025072482A (ja) | 2025-05-09 |
| AU2023270200B2 (en) | 2026-02-05 |
| US12084687B2 (en) | 2024-09-10 |
| CN110199018B (zh) | 2024-06-07 |
| KR20230113832A (ko) | 2023-08-01 |
| RU2019106319A (ru) | 2020-09-17 |
| KR20190038626A (ko) | 2019-04-08 |
| KR20250067190A (ko) | 2025-05-14 |
| JP7023929B2 (ja) | 2022-02-22 |
| JP2019524131A (ja) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019001672A (es) | Composiciones de poxvirus quiméricos y usos de las mismas. | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
| MX2018016273A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| CO2017010890A2 (es) | Derivados de maitansinoide, conjugados del mismo, y metodos de uso | |
| CY1122227T1 (el) | Ρυθμιση δραστικοτητας συμπληρωματος | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| ECSP17073743A (es) | Moduladores de k-ras | |
| MX394380B (es) | Compuestos dinucleótidos cíclicos para eltratamiento de cáncer | |
| UY37564A (es) | Aislados de lysinibacillus y usos de los mismos | |
| MX2018003491A (es) | Represores de htt y usos de estos. | |
| MX387596B (es) | Degradadores selectivos del receptor de estrógeno y sus usos. | |
| CR20160241A (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b | |
| CO2017004736A2 (es) | Péptidos macrociclicos útiles como inmunomoduladores | |
| MX2018007288A (es) | Anticuerpos neutralizantes para el virus de inmunodeficiencia humana. | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2016016301A (es) | Procesos de siembra en serie y usos de los mismos. | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| PE20170088A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| CL2016002245A1 (es) | Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
| MX2020002251A (es) | Compuestos espirociclicos y sus metodos de preparacion y uso. | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas |